Clinical Trial Update: Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study of oral panobinostat in adults with relapsed/refractory classical Hodgkin's lymphoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Classical Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-06-03